Journal Logo

Articles by N. Daver

PF205 RNA BASED IMMUNE SIGNATURES MAY PREDICT RESPONSES TO PD-1 INHIBITION AND AZACITIDINE TREATMENT IN ACUTE MYELOID LEUKEMIA (AML): A SUBSET ANALYSIS OF A PHASE 2 STUDY

Abbas, H.; Alfayez, M.; Wang, F.; More

HemaSphere. 3(S1):54-55, June 2019.

PF291 A PHASE 1B/2 CLINICAL STUDY OF TARGETED IDH1 INHIBITION WITH IVOSIDENIB, IN COMBINATION WITH THE BCL-2 INHIBITOR VENETOCLAX, FOR PATIENTS WITH IDH1-MUTATED (MIDH1) MYELOID MALIGNANCIES

Dinardo, C.; Takahashi, K.; Kadia, T.; More

HemaSphere. 3(S1):97, June 2019.

PF673 PHASE 1/2 STUDY OF RUXOLITINIB (RUX) PLUS DECITABINE (DAC) IN PATIENTS (PTS) WITH POST-MYELOPROLIFERATIVE NEOPLASM ACUTE MYELOID LEUKEMIA (POST-MPN AML)

Bose, P.; Verstovsek, S.; Naqvi, K.; More

HemaSphere. 3(S1):289-290, June 2019.

S829 SOTATERCEPT (ACE-011) IN SUBJECTS WITH MPN-ASSOCIATED MYELOFIBROSIS AND ANEMIA

Bose, P.; Pemmaraju, N.; Daver, N.; More

HemaSphere. 3(S1):367-368, June 2019.

PS1064 EXPLORATORY ANALYSIS OF OUTCOMES WITH SEQUENTIAL FLT3-INHIBITOR (FLT3I) BASED THERAPIES IN RELAPSED FLT3-MUTATED AML PATIENTS (PTS)

Alfayez, M.; Kantarjian, H.; Ravandi, F.; More

HemaSphere. 3(S1):481-482, June 2019.

S1615 SAFETY, EFFICACY, AND BIOMARKERS OF RESPONSE TO AZACITIDINE (AZA) WITH NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI), AND AZA WITH NIVO IN R/R ACUTE MYELOID LEUKEMIA: A NON-RANDOMIZED, PHASE 2 STUDY.

Daver, N.; Alfayez, M.; Garcia-Manero, G.; More

HemaSphere. 3(S1):745, June 2019.

PB1722 IMPACT OF CD33 AND ABCB1 SINGLE NUCLEOTIDE POLYMORPHISMS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROMES TREATED WITH DECITABINE PLUS GEMTUZUMAB OZOGAMICIN

Short, N.; Richard-Carpentier, G.; Kanagal-Shamanna, R.; More

HemaSphere. 3(S1):791-792, June 2019.